These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 30768787

  • 1. Anti-N and anti-Doa immunoglobulin G alloantibody-mediated delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease treated with eculizumab and HBOC-201: case report and review of the literature.
    Unnikrishnan A, Pelletier JPR, Bari S, Zumberg M, Shahmohamadi A, Spiess BD, Michael MJ, Harris N, Harrell D, Mandernach MW.
    Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787
    [Abstract] [Full Text] [Related]

  • 2. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.
    Talano JA, Hillery CA, Gottschall JL, Baylerian DM, Scott JP.
    Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582
    [Abstract] [Full Text] [Related]

  • 3. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab.
    Gupta S, Fenves A, Nance ST, Sykes DB, Dzik WS.
    Transfusion; 2015 Mar; 55(3):623-8. PubMed ID: 25257194
    [Abstract] [Full Text] [Related]

  • 4. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
    Vlachaki E, Gavriilaki E, Kafantari K, Adamidou D, Tsitsikas D, Chasapopoulou E, Anagnostopoulos A, Tsapas A.
    Hemoglobin; 2018 Mar; 42(5-6):339-341. PubMed ID: 30626228
    [Abstract] [Full Text] [Related]

  • 5. Immuno-hematological findings in Delayed Hemolytic Transfusion Reaction (DHTR).
    Thonier V.
    Transfus Clin Biol; 2019 May; 26(2):102-108. PubMed ID: 30885514
    [Abstract] [Full Text] [Related]

  • 6. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease.
    Noizat-Pirenne F, Bachir D, Chadebech P, Michel M, Plonquet A, Lecron JC, Galactéros F, Bierling P.
    Haematologica; 2007 Dec; 92(12):e132-5. PubMed ID: 18055978
    [Abstract] [Full Text] [Related]

  • 7. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.
    Balbuena-Merle R, Hendrickson JE.
    Transfus Clin Biol; 2019 May; 26(2):112-115. PubMed ID: 30857806
    [Abstract] [Full Text] [Related]

  • 8. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions.
    Aygun B, Padmanabhan S, Paley C, Chandrasekaran V.
    Transfusion; 2002 Jan; 42(1):37-43. PubMed ID: 11896310
    [Abstract] [Full Text] [Related]

  • 9. Management of delayed hemolytic transfusion reaction in sickle cell disease: Prevention, diagnosis, treatment.
    Pirenne F, Bartolucci P, Habibi A.
    Transfus Clin Biol; 2017 Sep; 24(3):227-231. PubMed ID: 28669521
    [Abstract] [Full Text] [Related]

  • 10. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab.
    Boonyasampant M, Weitz IC, Kay B, Boonchalermvichian C, Liebman HA, Shulman IA.
    Transfusion; 2015 Oct; 55(10):2398-403. PubMed ID: 25989361
    [Abstract] [Full Text] [Related]

  • 11. Anti-HI can cause a severe delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease patients.
    Ibanez C, Habibi A, Mekontso-Dessap A, Chadebech P, Chami B, Bierling P, Galactéros F, Rieux C, Nataf J, Bartolucci P, Peyrard T, Pirenne F.
    Transfusion; 2016 Jul; 56(7):1828-33. PubMed ID: 27145018
    [Abstract] [Full Text] [Related]

  • 12. Clinical presentation of delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease.
    Fasano RM, Miller MJ, Chonat S, Stowell SR.
    Transfus Clin Biol; 2019 May; 26(2):94-98. PubMed ID: 30837199
    [Abstract] [Full Text] [Related]

  • 13. Extended phenotyping does not preclude the occurrence of delayed haemolytic transfusion reactions in sickle cell disease.
    Gerritsma J, Bongaerts V, Eckhardt C, Heijboer H, Nur E, Biemond B, van der Schoot E, Fijnvandraat K, SCORE consortium.
    Br J Haematol; 2022 Feb; 196(3):769-776. PubMed ID: 34632580
    [Abstract] [Full Text] [Related]

  • 14. Prevention of potential delayed hemolytic transfusion reaction in two sickle cell patients using intravenous immunoglobulins and steroids before and after red blood cell exchange with antigen positive units and review literature.
    Shold J, Dasgupta A, Ye Z.
    Transfus Apher Sci; 2024 Jun; 63(3):103920. PubMed ID: 38570214
    [Abstract] [Full Text] [Related]

  • 15. Alloimmunization and hyperhemolysis in sickle cell disease.
    Pirenne F, Pondarré C.
    Hematology Am Soc Hematol Educ Program; 2023 Dec 08; 2023(1):653-659. PubMed ID: 38066873
    [Abstract] [Full Text] [Related]

  • 16. Alloimmunization in patients with sickle cell disease and underrecognition of accompanying delayed hemolytic transfusion reactions.
    Coleman S, Westhoff CM, Friedman DF, Chou ST.
    Transfusion; 2019 Jul 08; 59(7):2282-2291. PubMed ID: 31021439
    [Abstract] [Full Text] [Related]

  • 17. Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab.
    Lee LE, Beeler BW, Graham BC, Cap AP, Win N, Chen F.
    Transfusion; 2020 Jan 08; 60(1):30-35. PubMed ID: 31642065
    [Abstract] [Full Text] [Related]

  • 18. Acute Hyperhemolysis Syndrome in a Patient with Known Sickle Cell Anemia Refractory to Steroids and IVIG Treated with Tocilizumab and Erythropoietin: A Case Report and Review of Literature.
    Menakuru SR, Priscu A, Dhillon V, Salih A.
    Hematol Rep; 2022 Jul 21; 14(3):235-239. PubMed ID: 35893156
    [Abstract] [Full Text] [Related]

  • 19. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells.
    King KE, Shirey RS, Lankiewicz MW, Young-Ramsaran J, Ness PM.
    Transfusion; 1997 Apr 21; 37(4):376-81. PubMed ID: 9111274
    [Abstract] [Full Text] [Related]

  • 20. Utility of hemoglobin electrophoresis to distinguish between severe delayed hemolytic transfusion reaction versus hyperhemolysis syndrome.
    Lukin R, Law JY, Lokhandwala PM.
    Transfus Apher Sci; 2024 Jun 21; 63(3):103919. PubMed ID: 38582651
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.